Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-149

The PAA story is a compelling one for we that are in the know.

However, what can a layman perceive that we have achieved to date? There is sizzle, but no sausage.
When I mention to friends that I am invested in a company that has re-purposed a sheep drench to create a molecule that has potential to treat lymphoma in dogs, cancer and MND in humans and could be more efficient than a vaccine for Covid, their eyes glaze and the response is yeah, sure.

The average punter needs to observe broadcast of tangible results in mainstream media.
At this point, PAA is just the little Aussie battler with a feel-good story which will spin in and out of public consciousness like a shooting star.
"More testing required" is not a line that sticks in peoples memory.

Once we achieve a blockbuster outcome that shareholders are waiting for, then there will be no need for the Board to flick the switch to Hollywood. The media will come hunting the backstory.

So for the time being, even though I'm none too pleased with the SP, I feel that financial prudence regarding paid promotion is justified.

Just my thoughts on the PR situation...